Point-of-care troponin testing in patients with symptoms suggestive of acute coronary syndrome: A health technology assessment
Testing of cardiac biomarkers, such as cardiac troponin I or cardiac troponin T, has an important role in the diagnostic workup for acute coronary syndrome (ACS) (including acute myocardial infarction [AMI] and unstable angina), and in patients presenting with acute chest pain and a non-diagnostic e...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, [March 2016]
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Testing of cardiac biomarkers, such as cardiac troponin I or cardiac troponin T, has an important role in the diagnostic workup for acute coronary syndrome (ACS) (including acute myocardial infarction [AMI] and unstable angina), and in patients presenting with acute chest pain and a non-diagnostic electrocardiogram (ECG). Bedside testing of cardiac troponins (cTn) using point-of-care (POC) assays was developed to reduce the turnaround time of the standard tests performed in a central laboratory, and to expedite treatment. Given the introduction and increasing diffusion of POC cTn use, a review of its clinical and economic evidence is needed to inform decisions about its acquisition and use in emergency rooms and other in-hospital settings, as well as in rural health care centres and remote settings |
|---|---|
| Item Description: | "PROSPERO Registration Number: CRD42015023442." |
| Physical Description: | 1 PDF file (ix, 133 pages) illustrations |